Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Campbell, Lee ^a   Al Jayyoussi, Ghaith ^a   Gutteridge, Robert ^a   Gumbleton, Nigel ^a   Griffiths, Rosie ^a,b   Gumbleton, Simon ^a   Smith, Mathew W ^a   Griffiths, David F R ^b   Gumbleton, Mark ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Biomarkers; Caveolin 1; ERK 1 2; Invasion; Renal Cell Carcinoma

Indexed keywords

CAVEOLIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME PHOSPHORYLATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS REGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

CARCINOMA, RENAL CELL; CAVEOLIN 1; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HUMANS; KIDNEY NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84885365114     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-255     Document Type: Article

References (50)

1. Cohen AW, Razani B, Schubert W, Williams TM, Wang XB, Iyengar P, Brasaemle DL, Scherer PE, Lisanti MP. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes 2004, 53:1261-1270. 10.2337/diabetes.53.5.1261, 15111495.
2. Williams TM, Lisanti MP. The Caveolin genes: from cell biology to medicine. Ann Med 2004, 36:584-595. 10.1080/07853890410018899, 15768830.
3. Pike LJ. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta 2005, 1746:260-273. 10.1016/j.bbamcr.2005.05.005, 15951036.
4. Burgermeister E, Liscovitch M, Rocken C, Schmid RM, Ebert MP. Caveats of caveolin-1 in cancer progression. Cancer Lett 2008, 268:187-201. 10.1016/j.canlet.2008.03.055, 18482795.
5. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev 2008, 27:715-735. 10.1007/s10555-008-9160-9, 18506396.
6. Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, Ignatenko NA. Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells. Neoplasia 2008, 10:140-148. 10.1593/neo.07817, 2244689, 18283336.
7. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003, 23:9389-9404. 10.1128/MCB.23.24.9389-9404.2003, 309640, 14645548.
8. Arpaia E, Blaser H, Quintela-Fandino M, Duncan G, Leong HS, Ablack A, Nambiar SC, Lind EF, Silvester J, Fleming CK, et al. The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene 2012, 31:884-896. 10.1038/onc.2011.288, 3289793, 21765460.
9. Rossi S, Poliani PL, Cominelli M, Bozzato A, Vescovi R, Monti E, Fanzani A. Caveolin 1 is a marker of poor differentiation in Rhabdomyosarcoma. Eur J Cancer 2011, 47:761-772. 10.1016/j.ejca.2010.10.018, 21106364.
10. Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res 2010, 2:111-122. 3004586, 21188102.
11. Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Res 2011, 71:832-841. 10.1158/0008-5472.CAN-10-0730, 21148751.
12. Podar K, Anderson KC. Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett 2006, 233:10-15. 10.1016/j.canlet.2005.02.035, 16473666.
13. Elsheikh SE, Green AR, Rakha EA, Samaka RM, Ammar AA, Powe D, Reis-Filho JS, Ellis IO. Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer 2008, 99:327-334. 10.1038/sj.bjc.6604463, 2480981, 18612310.
14. Sagara Y, Mimori K, Yoshinaga K, Tanaka F, Nishida K, Ohno S, Inoue H, Mori M. Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer 2004, 91:959-965. 2409871, 15305200.
15. Bender FC, Reymond MA, Bron C, Quest AF. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 2000, 60:5870-5878.
16. Fine SW, Lisanti MP, Galbiati F, Li M. Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 2001, 115:719-724. 10.1309/YL54-CCU7-4V0P-FDUT, 11345836.
17. Chen HL, Fan LF, Gao J, Ouyang JP, Zhang YX. Differential expression and function of the caveolin-1 gene in non-small cell lung carcinoma. Oncol Rep 2011, 25:359-366.
18. Racine C, Belanger M, Hirabayashi H, Boucher M, Chakir J, Couet J. Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun 1999, 255:580-586. 10.1006/bbrc.1999.0236, 10049753.
19. Yoo SH, Park YS, Kim HR, Sung SW, Kim JH, Shim YS, Lee SD, Choi YL, Kim MK, Chung DH. Expression of caveolin-1 is associated with poor prognosis of patients with squamous cell carcinoma of the lung. Lung Cancer 2003, 42:195-202. 10.1016/S0169-5002(03)00287-3, 14568687.
20. Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, Cheville JC. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010, 183:1309-1315. 10.1016/j.juro.2009.12.035, 20171681.
21. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005, 23:202-212. 10.1007/s00345-004-0466-0, 15812574.
22. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 2008, 34:193-205. 10.1016/j.ctrv.2007.12.001, 18313224.
23. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011, 60:644-661. 10.1016/j.eururo.2011.06.041, 21741163.
24. Campbell L, Gumbleton M, Griffiths DF. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 2003, 89:1909-1913. 10.1038/sj.bjc.6601359, 2394459, 14612902.
25. Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M, Hayakawa M. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol 2004, 172:718-722. 10.1097/01.ju.0000130943.23317.08, 15247769.
26. Joo HJ, Oh DK, Kim YS, Lee KB, Kim SJ. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 2004, 93:291-296. 10.1111/j.1464-410X.2004.04604.x, 14764125.
27. Campbell L, Nuttall R, Griffiths D, Gumbleton M. Activated extracellular signal-regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma. Cancer 2009, 115:3457-3467. 10.1002/cncr.24389, 19526593.
28. Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DF. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer 2008, 98:931-940. 10.1038/sj.bjc.6604243, 2266860, 18283322.
29. Thomas NB, Hutcheson IR, Campbell L, Gee J, Taylor KM, Nicholson RI, Gumbleton M. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat 2010, 119:575-591. 10.1007/s10549-009-0355-8, 19288272.
30. Thomas DH, Verghese A, Kynaston HG, Griffiths DF. Analysis of the prognostic implications of different tumour margin types in renal cell carcinoma. Histopathology 2003, 43:374-380. 10.1046/j.1365-2559.2003.01721.x, 14511256.
31. Wang Y, Roche O, Xu C, Moriyama EH, Heir P, Chung J, Roos FC, Chen Y, Finak G, Milosevic M, et al. Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proc Natl Acad Sci U S A 2012, 109:4892-4897. 10.1073/pnas.1112129109, 3323978, 22411794.
32. Aubert S, Fauquette V, Hemon B, Lepoivre R, Briez N, Bernard D, van Seuningen I, Leroy X, Perrais M. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res 2009, 69:5707-5715. 10.1158/0008-5472.CAN-08-4905, 19549898.
33. Razorenova OV, Finger EC, Colavitti R, Chernikova SB, Boiko AD, Chan CK, Krieg A, Bedogni B, LaGory E, Weissman IL, et al. VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci USA 2011, 108:1931-1936. 10.1073/pnas.1011777108, 3033256, 21233420.
34. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 2009, 218:530-539. 10.1002/path.2567, 19455604.
35. Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ. Surveillance for renal cell carcinoma: why and how? When and how often?. Urol Oncol 2008, 26:550-554. 10.1016/j.urolonc.2007.05.026, 18774472.
36. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007, 5:379-385. 10.3816/CGC.2007.n.020, 17956710.
37. Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer 2009, 115:3651-3660. 10.1002/cncr.24438, 19526589.
38. Park J, Bae E, Lee C, Yoon SS, Chae YS, Ahn KS, Won NH. RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis. Tumour Biol 2010, 31:643-650. 10.1007/s13277-010-0081-1, 20820979.
39. Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, Tatarano S, Yonezawa T, Kinoshita T, Nakagawa M, Enokida H. microRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway. J Urol 2013, 190:1059-1068. 10.1016/j.juro.2013.02.089, 23454155.
40. Tringali C, Lupo B, Silvestri I, Papini N, Anastasia L, Tettamanti G, Venerando B. The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling beta1 integrin internalization and recycling. J Biol Chem 2012, 287:42835-42845. 10.1074/jbc.M112.407718, 23139422.
41. Sowa G. Novel insights into the role of caveolin-2 in cell- and tissue-specific signaling and function. Biochem Res Int 2011, 2011:809259. 3249596, 22229094.
42. Evdokimova V, Tognon C, Ng T, Sorensen PH. Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1. Cell Cycle 2009, 8:2901-2906. 10.4161/cc.8.18.9537, 19713745.
43. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009, 15:402-415. 10.1016/j.ccr.2009.03.017, 19411069.
44. Draberova E, Vinopal S, Morfini G, Liu PS, Sladkova V, Sulimenko T, Burns MR, Solowska J, Kulandaivel K, de Chadarevian JP, et al. Microtubule-severing ATPase spastin in glioblastoma: increased expression in human glioblastoma cell lines and inverse roles in cell motility and proliferation. J Neuropathol Exp Neurol 2011, 70:811-826. 3400501, 21865889.
45. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010, 16:3628-3638. 10.1158/1078-0432.CCR-09-3022, 2905505, 20606035.
46. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003, 63:917-926. 10.1046/j.1523-1755.2003.00805.x, 12631072.
47. Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 2009, 7:1781-1791. 10.1158/1541-7786.MCR-09-0255, 19903767.
48. Kofman AE, McGraw MR, Payne CJ. Rapamycin increases oxidative stress response gene expression in adult stem cells. Aging (Albany NY) 2012, 4:279-289. 3371763, 22529334.
49. Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol 2008, 28:3281-3289. 10.1128/MCB.00310-08, 2423144, 18332125.
50. Dasari A, Bartholomew JN, Volonte D, Galbiati F. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 2006, 66:10805-10814. 10.1158/0008-5472.CAN-06-1236, 17108117.